Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings Inc (RANI) is a clinical-stage biotherapeutics leader developing oral alternatives to injectable biologic medications through its patented RaniPill technology. This page provides investors and industry observers with timely updates on corporate milestones, clinical trial progress, and strategic initiatives shaping the future of non-invasive drug administration.
Access official press releases, financial disclosures, and third-party analysis covering RANI's advancements in transforming treatments for chronic diseases. Key updates include trial results for oral biologic formulations, intellectual property developments, partnership announcements with pharmaceutical collaborators, and quarterly performance reports.
Bookmark this page for streamlined tracking of RANI's progress in addressing critical challenges in drug delivery. Return regularly to monitor how the company's capsule-based technology could impact treatment adherence, patient comfort, and the broader $500B+ biologics market.
Rani Therapeutics Holdings (Nasdaq: RANI) has announced a $10.0 million registered direct offering of its Class A common stock and warrants. The company will sell 3,000,000 shares of common stock and pre-funded warrants for 333,333 shares, along with Series C common warrants for up to 3,333,333 shares. Each share or pre-funded warrant is priced at $3.00, bundled with a Series C warrant. The Series C warrants have a $3.00 exercise price and a 5-year expiration. Rani will also cancel all outstanding Series A warrants issued on July 22, 2024. Maxim Group is the sole placement agent, with the offering expected to close around October 16, 2024. The proceeds will be used to support Rani's clinical-stage biotherapeutics work on oral delivery of biologics and drugs.
Rani Therapeutics, a Nasdaq-listed clinical-stage biotherapeutics company (RANI), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company, which focuses on oral delivery of biologics and drugs, will be represented by CEO Talat Imran and CFO Svai Sanford in a fireside chat.
The event is scheduled for Thursday, October 17, 2024, from 11:30 am to 12:00 pm E.T. in Track 2. Interested parties can access the live webcast of the conference through a provided registration link. This participation highlights Rani Therapeutics' engagement with the investment community and its commitment to sharing insights about its innovative approach to drug delivery.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company focusing on oral delivery of biologics and drugs, has announced its participation in two major investor conferences in September 2024. The company will be present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10 and the 2024 Cantor Global Healthcare Conference on September 18, both in New York City.
CEO Talat Imran will represent Rani at both events, delivering a company presentation at the H.C. Wainwright conference and participating in a fireside chat at the Cantor conference. Both events will also include one-on-one investor meetings. Interested parties can access live webcasts of these presentations through the 'Events' section of Rani Therapeutics' website, with replays available after the events conclude.
Rani Therapeutics (Nasdaq: RANI) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Partnership with ProGen to develop RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, with Phase 1 study expected in 2025.
2. Completed equity offering with gross proceeds of $10.0 million.
3. Presented clinical and preclinical data on oral delivery of ustekinumab biosimilar via RaniPill® Capsule at DDW 2024.
4. Q2 2024 financials: Cash and equivalents at $30.9 million, R&D expenses decreased to $6.1 million, G&A expenses decreased to $6.4 million, net loss reduced to $13.4 million.
5. ProGen presented positive Phase 1 data on PG-102 (GLP-1/GLP-2 dual agonist) at ADA 2024 conference.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company focusing on oral delivery of biologics and drugs, has announced its participation in two upcoming investor conferences in August 2024. The company will attend the BTIG Virtual Biotechnology Conference on August 5th-6th, participating in one-on-one investor meetings. Additionally, Rani will present at the Canaccord 44th Annual Growth Conference in Boston on August 13th at 3:30 PM ET, featuring a company presentation by CEO Talat Imran and investor meetings.
Interested parties can access live webcasts of these events through the 'Events' section of Rani Therapeutics' website. Webcast replays will be available after the presentations conclude.
Rani Therapeutics Holdings (Nasdaq: RANI), a clinical-stage biotherapeutics company, has announced a $10.0 million registered direct offering. The offering includes 2,800,000 shares of Class A common stock and pre-funded warrants for 446,753 shares, along with Series A and B common warrants. Each share or pre-funded warrant is sold with one Series A and one Series B warrant at $3.08. The warrants have an exercise price of $3.08 and will be exercisable after 6 months. Series A warrants expire in 18 months, while Series B warrants expire in 5.5 years. Maxim Group is the sole placement agent. The offering is expected to close around July 23, 2024, subject to customary conditions.
Rani Therapeutics announced a partnership with ProGen to develop RT-114, an oral obesity treatment using RaniPill® capsules and ProGen's dual agonist, PG-102. The collaboration features a 50/50 cost and revenue share, with Rani leading development in the US, Europe, Canada, and Australia, while ProGen heads efforts elsewhere. The RT-114 program aims to offer a weekly oral dose, potentially improving patient adherence and therapeutic effects. Previous clinical studies of both the RaniPill® platform and PG-102 have shown promising results in bioavailability and safety profiles.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, announced participation in two investor conferences in May 2024. The H.C. Wainwright 2nd Annual BioConnect Investor Conference will be held on May 20th at Nasdaq Headquarters, New York City, featuring a fireside chat and 1x1 investor meetings with CEO Talat Imran. The UBS Spring Biotech Conference will take place on May 21st at UBS, New York City, consisting of 1x1 investor meetings. Live webcast for the H.C. Wainright Conference will be available on Rani's website.
Rani Therapeutics, a clinical-stage biotherapeutics company, will present clinical and preclinical data on their oral delivery platform, the RaniPill® capsule, at Digestive Disease Week 2024. The data will focus on the oral delivery of an Ustekinumab biosimilar, showcasing high bioavailability in healthy human participants and canines. The presentations will take place virtually and in-person on May 18-21, 2024, in Washington, DC.
Rani Therapeutics reported positive topline results from a Phase 1 study for RT-111, an oral anti-Interleukin 12/23 antibody, and plans to initiate a Phase 2 clinical trial for RT-102 for osteoporosis treatment in 2024. The company's RaniPill HC is set for potential Phase 1 trials later in 2024. Financially, Rani Therapeutics had $39.6 million in cash, cash equivalents, and marketable securities as of March 31, 2024, with a decrease in research and development expenses compared to the previous year.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
